CSL Completes Transaction to Acquire a Majority Stake in Chinese Plasma Fractionator
CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that it has closed a joint venture transaction with Humanwell Healthcare Group Co. Ltd. (Humanwell; Shanghai exchange: 600079) to acquire a majority stake in plasma-derived therapies manufacturer Wuhan Zhong Yuan Rui De Biological…
Read MoreGlobal Connections Fund Bridging Grant Awardees 2017
The Global Connections Fund is an initiative of the Australian Government’s National Innovation and Science Agenda (NISA) funded by the Department of Industry, Innovation and Science. You can see Bridging Grant Awardees here
Read MorePositive Data from Cynata MSCs in Second Preclinical Asthma Study
Positive Data from Cynata MSCs in Second Preclinical Asthma Study • Clear efficacy data for Cynata’s proprietary Cymerus™ MSCs in second preclinical study in a clinically-relevant model of asthma • Cymerus MSCs caused significantly greater reduction of airway…
Read MoreRegenerative Medicine Industry Interface – a new industry collaboration in Victoria
Announcing RMI2 The Regenerative Medicine Industry Interface Regenerative Medicine An emerging field of medical science, regenerative medicine incorporates the use of cells, factors, and other biological building blocks, along with bioengineered materials and technologies for widespread clinical applications.…
Read MoreVictorian medical emergency company Medical Developments International emerges as global leader
A Victorian emergency medicine company has risen to become a global leader, thanks to its range of respiratory medications. Offering new devices for asthma and chronic obstructive pulmonary disease (COPD), Medical Developments International (MDI), is turning its attention…
Read MoreNew collaboration for Alzheimer’s Research – SVI & Janssen
SVI has entered into a collaboration and license agreement with Janssen Pharmaceuticals, Inc. (“Janssen”), one of the Janssen Pharmaceuticals Companies of Johnson & Johnson. The partnership is aimed at developing and commercialising small molecule modulators of microglial function…
Read MoreAn Australian first: Monash launches new Diabetes Department
Monash University today officially launched its new Department of Diabetes – the first and only university department in Australia dedicated to the disease. Opened by the Honourable Greg Hunt MP, Minister for Health, the new Department is a…
Read MoreLBT Innovations Receives 2017 SA Science Excellence Award for Collaboration
LBT Innovations Ltd (LBT) has been awarded the 2017 SA Science Excellence Award for “Excellence in Research Collaboration”. The award recognises excellence in developing a world leading intelligent medical device in South Australia, and the collaboration between the…
Read MoreVivaGel® BV demonstrated statistically significant efficacy in two pivotal phase 3 trials
VivaGel® BV consistently resulted in reduced rates of BV recurrence by the primary efficacy endpoint and five secondary efficacy measures, and delayed time to first recurrence VivaGel® BV resulted in sustained benefits 3 months after cessation of treatment…
Read MoreLBT’S Woundvue™ Prototype to be Used at Central Adelaide Health Network
Australian medical technology company LBT Innovations Limited (ASX:LBT) has entered a collaboration agreement with Central Adelaide Local Health Network (CALHN) Vascular and Endovascular Services, to use LBT’s novel WoundVue™ prototype device in the clinical trial, “Predicting outcomes in…
Read More
